TFS was selected by a small biotech company to provide full CRO service to conduct a global, exploratory immune oncology phase II study in Metastatic Renal Cell Carcinoma. Service included: Project Management, Site Management, Regulatory Management, Data Management, Safety, Medical Writing and Biostatistics. Study was started in April 2015, recruitment was ended December 2017, last patient last visit was conducted 17th June 2019 and DBL and Top Line Result was delivered in August 2019.
Metastatic Renal Cell Carcinoma Case Study
